Story

Silence Therapeutics Stock Slides on Discounted $175 Million Share Offering

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Silence Therapeutics Stock Slides on Discounted $175 Million Share Offering
Text size
Background

Shares of Silence Therapeutics (NASDAQ: SLN) fell in pre-market trading after the biotechnology company priced a significant underwritten public offering at a discount to its recent market value. The move is intended to raise approximately $175 million in gross proceeds, but the pricing has created near-term pressure on the stock.

Details of the Offering

The company announced it is offering approximately 12.96 million American Depositary Shares (ADSs) to the public at a price of $13.50 per share. This price represents a notable discount from where the stock had been trading prior to the announcement.

Underwriters have a 30-day option to purchase up to an additional 1.94 million ADSs, which could increase the total capital raised but would also result in further shareholder dilution. Such offerings, while common for development-stage biotech firms needing capital, often cause a stock's price to fall toward the offering price as existing shares are devalued.

Context of Positive Clinical News

The capital raise comes just days after Silence Therapeutics reported a significant clinical milestone. On August 10, the company disclosed positive topline results from its Phase 2 SANRECO trial for divesiran, a first-in-class siRNA therapy for the blood disorder polycythemia vera.

Sample IUX Markets – In-articleAd

Partially buffering the negative sentiment from the offering, Morgan Stanley maintained its Overweight rating on the stock and raised its price target to $32 from $25. This indicates underlying confidence from analysts in the company's long-term prospects, though it was not enough to prevent the stock's immediate slide.

Market Reaction

In pre-open trading, Silence Therapeutics stock slipped 1.8%, a move attributed directly to the offering's dilutive effect. The decline occurred while the broader U.S. market showed strength, with major indices like the NASDAQ and S&P 500 trading higher, confirming that the sell-off was company-specific.

For investors, the discounted offering has overshadowed the positive clinical trial data and bullish analyst outlook in the short term. The immediate reality of dilution is anchoring the stock's price, demonstrating a classic tension between a company's long-term potential and its near-term financing needs.

Read next

More on Stocks
Back to latest news

LATEST